+919405117673
Everolimus Tablets 5mg/10mg Packaging Considerations for UK Medicine Imports

A carton produced for the Indian market is not automatically suitable for sale or distribution in the UK. You need to confirm the destination territory, lawful import route, English regulatory information, pack configuration, batch evidence and transport controls before accepting an everolimus shipment.

Key takeaways

  • Confirm Great Britain or Northern Ireland before approving artwork.
  • Verify the lawful authorisation and import route before shipment.
  • Treat 5 mg and 10 mg packs as separate purchase items.
  • Match batch details, release documents and transport records before receipt.

Confirm the UK territory and lawful supply route before reviewing artwork

An Indian manufacturing licence does not, by itself, make an everolimus pack lawful for UK supply. Confirm whether the shipment is entering Great Britain or Northern Ireland, then match it to the correct authorisation and import route before assessing the artwork.

1. For Great Britain medicine imports, verify that the exact everolimus product and presentation are covered by a UK marketing authorisation under the Human Medicines Regulations. Search the product, strength, pharmaceutical form and pack size in the MHRA medicines database; an Indian registration, EU approval or supplier catalogue is not enough.

2. Confirm who is legally importing and wholesaling the tablets. A non-UK or non-EEA shipment generally requires a Manufacturer/Importer Authorisation (MIA), including the required quality-control and batch-certification arrangements, while onward commercial distribution requires a wholesale dealer authorisation. Obtain the authorisation numbers and check that their scopes cover the proposed activity.

3. Apply Northern Ireland medicines rules when the pack is placed on the Northern Ireland market. Confirm the applicable EU medicines authorisation route and EU safety-feature obligations, including the unique identifier and anti-tampering requirements where they apply.

4. Do not treat an EU serialisation code as a substitute for the Great Britain route. A product can contain the same active ingredient yet remain unsuitable if its manufacturer, importer, presentation or labelling falls outside the authorisation covering your territory. Reject the quotation until those details reconcile.

Check every required item on the carton, leaflet and tablet pack

A UK-compliant presentation must keep English labelling readable on every layer, not just on a replacement sticker. Confirm that the exact strength, tablet count, blister or bottle format and leaflet version match the approved presentation; 5 mg and 10 mg packs are not interchangeable.

LayerInformation to checkWhat can disqualify the pack
Secondary packaging: outer cartonEverolimus, 5 mg or 10 mg, tablets, oral route where stated, active substance, tablet count, storage conditions, batch number, expiry date, marketing-authorisation holder and importer or parallel-distributor details, prescription-status wording, and required tamper evidenceA covered batch number, unclear strength, missing UK supply details, absent Braille for the product name, or a broken seal
Primary packaging: blister strip or bottleProduct name, strength, batch number and expiry date must remain legible; confirm the strip or bottle is sealed, undamaged and traceable to the cartonA torn blister, loose seal, illegible print, unexplained bottle presentation or tablets exposed to damage
Patient information leafletThe approved English patient information leaflet must accompany the pack and match the product, strength and presentation, including directions, warnings, handling and disposal adviceA foreign-language leaflet, missing leaflet, wrong strength or leaflet text that does not match the authorised medicine

Ask for the manufacturing date where it is printed, plus batch-level release records. An over-label must not obscure storage instructions, expiry, batch details or tamper evidence. Because everolimus tablets should remain intact, reject packs with breakage, leakage or unsafe handling instructions.

Control the 5 mg and 10 mg presentations as separate purchase items

Create separate purchase order lines for Everolimus 5 mg and Everolimus 10 mg. Treat each as its own stock-keeping item, because strength alone does not identify the commercial pack. Record the approved presentation, tablet count, blister configuration or bottle presentation, and the exact UK-authorised product information linked to the quoted batch.

  • State the strength in numerals and words where your system allows: “Everolimus 5 mg” or “Everolimus 10 mg”; never use “everolimus tablets” alone.
  • Specify the tablet count per carton and per blister, such as 30 tablets in 3 blisters of 10; do not accept a substituted count without written approval.
  • Name the permitted pack format, including blister material or bottle presentation, and prohibit mixed cartons containing both strengths.
  • State “full cartons only” if split packs are not authorised for the order; require separate outer-carton identification for every partial shipment.

At picking and packing, scan or read the strength, count and batch against the purchase order before sealing each carton. At receipt, quarantine any mixed cartons, unlabelled inner packs, opened blisters, damaged tablets or a count that differs from the order.

Everolimus tablets are intended to remain intact, and the original package protects them from light and moisture; do not decant them into ordinary bottles without supporting stability evidence.

Match the physical batch to release documents and transport conditions

Accept the shipment only when the batch number, strength, presentation and manufacturing site on the physical pack match every release record. A genuine-looking carton does not prove that the stock is authorised, correctly relabelled or free from diversion.

Match these items before receipt:

  • The certificate of analysis and batch release documentation must identify the same batch, product, 5 mg or 10 mg strength, tablet presentation, manufacturer and expiry date.
  • The certificate of conformity and packing records must describe the supplied carton, blister or bottle, tablet count and packaging configuration. Check that the physical seal, tamper evidence and printed batch number agree.
  • Confirm the manufacturing site against the UK authorisation and retain evidence that the presentation is covered. An Indian registration or supplier catalogue is not enough.
  • Record the expiry date and remaining shelf life against the purchase order and receiving requirement. Do not accept a substituted date or relabelled pack without traceable approval.
  • Review temperature logger results, route records and GDP transport documentation. “Below 25°C” describes storage, not proof that unqualified ambient transport protected the shipment; investigate and document every temperature excursion.

Everolimus tablets require protection from light and moisture in the original package. Stability evidence must therefore support the actual pack and route, not just the active ingredient. Repacking into a bulk bottle or dispensing container needs specific stability justification, while any over-label must leave the batch, expiry, strength, storage statement and origin traceable.

Build the import file around the consignee, route and approved presentation

Do not approve the shipment until the named consignee, UK route and exact presentation match across the purchase order, MHRA medicines database record and export documents. A 5 mg or 10 mg strength does not identify the tablet count, blister configuration or approved leaflet.

Request this file before dispatch:

File elementWhat to verifyFailure it prevents
Commercial invoice and packing listProduct name, strength, quantity, pack size, batch, expiry, unit value, seller, consignee and IncotermWrong count, undervaluation or an untraceable batch
Airway bill or bill of ladingConsignee, shipper, route, packages and shipment reference match the invoice and packing listDelivery to an unauthorised party or route-document mismatch
Customs commodity classification and origin informationThe declared HS code, India as origin where applicable, manufacturer and supporting origin statementClearance delays, incorrect duty treatment or misdeclaration
Consignee authorisation and licence evidenceThe consignee’s wholesale, import or other required licence, plus evidence supporting the selected UK supply routeA shipment that cannot lawfully enter or be supplied
Batch fileCertificate of analysis, release evidence, packing record, shelf-life statement and temperature recordsAccepting stock that is relabelled, diverted or poorly transported

Cordium Pharmaceuticals Pvt Ltd can help reconcile supplier documents, the consignee’s licence evidence and the approved UK presentation before a quotation becomes a shipment. Ask for corrected documents, not handwritten amendments, when any identifier differs.

Related products

Evermil Tablets – Everolimus 5mg & 10mg

Oncology Medicine

Evermil Tablets – Everolimus 5mg & 10mg

Evermil Tablets contain everolimus, a medicine that belongs to the mTOR inhibitor group.

View product →
Rolimus Tablets: Product Details, Strengths, Uses & FAQs

Oncology Medicine

Rolimus Tablets: Product Details, Strengths, Uses & FAQs

Rolimus Tablets contain everolimus, a prescription medicine that belongs to the mTOR inhibitor class.

Frequently asked questions

  • Why must importers confirm the UK territory before reviewing everolimus packaging?

    Great Britain and Northern Ireland use different regulatory and supply arrangements. Confirm the destination territory first, then match the product to the correct authorisation and import route.

  • What should you check on an everolimus carton, leaflet and tablet pack?

    Check the approved product name, strength, pharmaceutical form, pack size, batch number, expiry date, storage wording, leaflet and presentation details against the authorised artwork.

  • Why should 5 mg and 10 mg everolimus tablets be managed separately?

    Treat each strength as a separate purchase item so quotations, artwork, batch records, release documents and quantities cannot be confused.

  • How do you match the physical everolimus batch to its import documents?

    Compare the batch number, expiry date, strength, pack size and quantities on the cartons and blister packs with the release documents and shipping records.

  • What belongs in an everolimus import file?

    Build the file around the consignee, destination territory, approved presentation, lawful supply route, batch evidence, release documents and transport conditions.

Related products

Evertor Tablets – Product Information, Strengths, Benefits and FAQs

Oncology Medicine

Evertor Tablets – Product Information, Strengths, Benefits and FAQs

Evertor Tablets (Everolimus): Product Overview Evertor Tablets contain everolimus, a prescription medicine used in the management of certain cancers...

Torinat Tablets – Everolimus 5mg and 10mg

Oncology Medicine

Torinat Tablets – Everolimus 5mg and 10mg

Torinat Tablets contain Everolimus, an mTOR inhibitor used under medical supervision for specific cancer treatments and other approved medical...

View product →
Rapact Tablets – Everolimus Medicine in India

Oncology Medicine

Rapact Tablets – Everolimus Medicine in India

Product Description Rapact Tablets contain everolimus, an active pharmaceutical ingredient belonging to the mTOR inhibitor class.

View product →
Nov 14th, 2026 5:17 PM